Marc Ladanyi

Research interests

Publications

• Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients

  Cell · 2022 · https://doi.org/10.1016/j.cell.2022.01.003

• Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials

  The Lancet Oncology · 2020 · https://doi.org/10.1016/s1470-2045(19)30856-3

• Cancer therapy shapes the fitness landscape of clonal hematopoiesis

  Nature Genetics · 2020 · 10.1038/s41588-020-00710-0

• Tumor mutational load predicts survival after immunotherapy across multiple cancer types

  Nature Genetics · 2019 · https://doi.org/10.1038/s41588-018-0312-8

• High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants

  Nature Medicine · 2019 · https://doi.org/10.1038/s41591-019-0652-7

• Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types

  Cell Reports · 2018 · 10.1016/j.celrep.2018.01.088

• Driver Fusions and Their Implications in the Development and Treatment of Human Cancers

  Cell Reports · 2018 · https://doi.org/10.1016/j.celrep.2018.03.050

• Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children

  New England Journal of Medicine · 2018 · https://doi.org/10.1056/nejmoa1714448

• An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics

  Cell · 2018 · https://doi.org/10.1016/j.cell.2018.02.052

• Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer

  Cell · 2018 · 10.1016/j.cell.2018.03.022

• Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation

  Cell · 2018 · 10.1016/j.cell.2018.03.034

• The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers

  Cancer Cell · 2018 · 10.1016/j.ccell.2018.08.008

• Molecular Determinants of Response to Anti–Programmed Cell Death (PD)-1 and Anti–Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non–Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing

  Journal of Clinical Oncology · 2018 · 10.1200/jco.2017.75.3384

• Genomic and Functional Approaches to Understanding Cancer Aneuploidy

  Cancer Cell · 2018 · 10.1016/j.ccell.2018.03.007

• Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images

  Cell Reports · 2018 · 10.1016/j.celrep.2018.03.086

• Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients

  Cancer Cell · 2018 · 10.1016/j.ccell.2018.07.001

• Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines

  Cell Systems · 2018 · 10.1016/j.cels.2018.03.002

• Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology

  Archives of Pathology & Laboratory Medicine · 2018 · 10.5858/arpa.2017-0388-cp

• Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas

  Cancer Cell · 2018 · 10.1016/j.ccell.2018.03.010

• Integrative Molecular Characterization of Malignant Pleural Mesothelioma

  Cancer Discovery · 2018 · 10.1158/2159-8290.cd-18-0804

• Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer

  Cell Reports · 2018 · 10.1016/j.celrep.2018.10.001

• lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer

  Cancer Cell · 2018 · 10.1016/j.ccell.2018.03.006

• Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients

  Nature Medicine · 2017 · https://doi.org/10.1038/nm.4333

• OncoKB: A Precision Oncology Knowledge Base

  JCO Precision Oncology · 2017 · 10.1200/po.17.00011

• AACR Project GENIE: Powering Precision Medicine through an International Consortium

  Cancer Discovery · 2017 · 10.1158/2159-8290.cd-17-0151

• Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience

  Journal of Thoracic Oncology · 2015 · 10.1097/jto.0000000000000516

• Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)

  Journal of Molecular Diagnostics · 2015 · 10.1016/j.jmoldx.2014.12.006

• Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs

  JAMA · 2014 · 10.1001/jama.2014.3741

• Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR -Mutant Lung Cancers

  Clinical Cancer Research · 2013 · 10.1158/1078-0432.ccr-12-2246

• Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology

  Journal of Thoracic Oncology · 2013 · 10.1097/jto.0b013e318290868f

• Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer

  Nature Genetics · 2012 · 10.1038/ng.2330

• The landscape of somatic copy-number alteration across human cancers

  Nature · 2010 · https://doi.org/10.1038/nature08822

• Somatic mutations affect key pathways in lung adenocarcinoma

  Nature · 2008 · 10.1038/nature07423

• MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

  Proceedings of the National Academy of Sciences · 2007 · 10.1073/pnas.0710370104

• Characterizing the cancer genome in lung adenocarcinoma

  Nature · 2007 · 10.1038/nature06358

• KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib

  PLoS Medicine · 2005 · 10.1371/journal.pmed.0020017

• Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks

  Nature Medicine · 2001 · 10.1038/89044

• Infusions of Donor Leukocytes to Treat Epstein-Barr Virus-Associated Lymphoproliferative Disorders after Allogeneic Bone Marrow Transplantation

  New England Journal of Medicine · 1994 · 10.1056/nejm199404283301703

Current projects

No projects listed.